Core Insights - Lila Biologics has entered a global licensing and multi-target research collaboration with Eli Lilly to develop novel radioligand therapies for solid tumors [1] - The company has launched two AI/ML-driven protein therapeutic platforms aimed at treating cancer and non-oncology diseases [1][5] - Lila's proprietary technology focuses on optimizing drug-like properties of proteins to create transformative therapeutics [2][4] Company Overview - Lila Biologics was founded in late 2023, emerging from the lab of Nobel Laureate David Baker at the University of Washington [6] - The company is headquartered in Seattle, WA, and aims to revolutionize patient care through advanced protein design technologies [5][6] Technology and Platforms - Lila's Targeted Radiotherapy (TRT) platform is designed for solid tumor indications, while the Long-Acting Injectables (LAI) platform targets non-oncology diseases [5] - The LILADD™ framework allows rapid discovery and optimization of protein-based biologics with first- or best-in-class potential [2] Collaboration with Eli Lilly - The collaboration will focus on generating novel tumor-targeting radiopharmaceuticals, with Lila designing precision-targeted proteins and Lilly handling clinical development and commercialization [3] - Lila retains full asset rights to its proprietary RLT and LAI pipelines, separate from the collaborative efforts with Lilly [3]